If the treatment landscape for prostate cancer is to be transformed,clinicians and scientists must work together ever more closely.Prostate cancer defeats physicians when patients are not accurately stratified accordi...If the treatment landscape for prostate cancer is to be transformed,clinicians and scientists must work together ever more closely.Prostate cancer defeats physicians when patients are not accurately stratified according to patients’risk of dying of disease,when the effects of tumor heterogeneity are insufficiently understood,and when attempts at therapy by clinicians spur further disease evolution and the emergence of new resistance mechanisms.At the same time,clinicians’over-treat men who in reality do not need it,and some of those men needlessly suffer long term side effects as a result.This commentary is aimed at stimulating debate about how we as clinicians and scientists can assist one another and improve our knowledge to the benefit of patients dying from metastatic disease.展开更多
文摘If the treatment landscape for prostate cancer is to be transformed,clinicians and scientists must work together ever more closely.Prostate cancer defeats physicians when patients are not accurately stratified according to patients’risk of dying of disease,when the effects of tumor heterogeneity are insufficiently understood,and when attempts at therapy by clinicians spur further disease evolution and the emergence of new resistance mechanisms.At the same time,clinicians’over-treat men who in reality do not need it,and some of those men needlessly suffer long term side effects as a result.This commentary is aimed at stimulating debate about how we as clinicians and scientists can assist one another and improve our knowledge to the benefit of patients dying from metastatic disease.
